S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
Log in

NASDAQ:CVETCovetrus Stock Price, Forecast & News

$6.95
+0.12 (+1.76 %)
(As of 04/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.87
Now: $6.95
$7.52
50-Day Range
$5.64
MA: $9.28
$12.95
52-Week Range
$4.05
Now: $6.95
$33.70
Volume994,140 shs
Average Volume1.83 million shs
Market Capitalization$776.37 million
P/E RatioN/A
Dividend YieldN/A
Beta1.84
Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.70 out of 5 stars


Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:CVET
CUSIPN/A
CIKN/A
Phone888-280-2221

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.98 billion
Cash Flow$11.58 per share
Book Value$11.20 per share

Profitability

Net Income$-1,019,000,000.00

Miscellaneous

Employees5,500
Market Cap$776.37 million
Next Earnings Date5/20/2020 (Estimated)
OptionableNot Optionable

Receive CVET News and Ratings via Email

Sign-up to receive the latest news and ratings for CVET and its competitors with MarketBeat's FREE daily newsletter.


Covetrus (NASDAQ:CVET) Frequently Asked Questions

How has Covetrus' stock been impacted by COVID-19 (Coronavirus)?

Covetrus' stock was trading at $9.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CVET stock has decreased by 23.1% and is now trading at $6.95. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Covetrus?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Covetrus.

When is Covetrus' next earnings date?

Covetrus is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Covetrus.

How were Covetrus' earnings last quarter?

Covetrus Inc (NASDAQ:CVET) announced its quarterly earnings results on Tuesday, March, 3rd. The company reported $0.18 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.12 by $0.06. The company had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $985.29 million. Covetrus had a negative net margin of 24.30% and a positive return on equity of 3.70%. The business's quarterly revenue was up 11.6% compared to the same quarter last year. View Covetrus' earnings history.

What guidance has Covetrus issued on next quarter's earnings?

Covetrus issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, March, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $4.025-4.125 billion, compared to the consensus revenue estimate of $4.14 billion.

What price target have analysts set for CVET?

6 Wall Street analysts have issued twelve-month price targets for Covetrus' stock. Their forecasts range from $11.00 to $21.00. On average, they anticipate Covetrus' share price to reach $15.75 in the next year. This suggests a possible upside of 126.6% from the stock's current price. View analysts' price targets for Covetrus.

Has Covetrus been receiving favorable news coverage?

News headlines about CVET stock have been trending very negative on Tuesday, according to InfoTrie. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Covetrus earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutCovetrus.

Are investors shorting Covetrus?

Covetrus saw a increase in short interest in February. As of February 28th, there was short interest totaling 19,820,000 shares, an increase of 12.4% from the February 13th total of 17,630,000 shares. Based on an average daily volume of 1,540,000 shares, the days-to-cover ratio is presently 12.9 days. Currently, 20.5% of the company's stock are short sold. View Covetrus' Current Options Chain.

Who are some of Covetrus' key competitors?

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include Uber Technologies (UBER), Century Aluminum (CENX), IDEXX Laboratories (IDXX), RealReal (REAL), SVMK (SVMK), Chewy (CHWY), Evolent Health (EVH), Tapestry (TPR), Verizon Communications (VZ) and Advanced Micro Devices (AMD).

Who are Covetrus' key executives?

Covetrus' management team includes the following people:
  • Benjamin J. Shaw, President, Chief Executive Officer & Director
  • Christine Tomlinson Komola, Chief Financial Officer & Executive Vice President
  • Matthew Leonard, Executive VP & President-North America
  • Jim Young, Chief Human Resources Officer & Senior VP
  • Erin Powers Brennan, Secretary, Senior Vice President & General Counsel

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Who are Covetrus' major shareholders?

Covetrus' stock is owned by a variety of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.08%). Company insiders that own Covetrus stock include Benjamin Shaw, Betsy S Atkins, David Christopher Dollar, Erin Powers Brennan and Timothy Ludlow. View institutional ownership trends for Covetrus.

Which major investors are buying Covetrus stock?

CVET stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Covetrus stock in the last two years include Benjamin Shaw, and Erin Powers Brennan. View insider buying and selling activity for Covetrus.

How do I buy shares of Covetrus?

Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $6.95.

How big of a company is Covetrus?

Covetrus has a market capitalization of $776.37 million and generates $3.98 billion in revenue each year. The company earns $-1,019,000,000.00 in net income (profit) each year or $0.79 on an earnings per share basis. Covetrus employs 5,500 workers across the globe. View additional information about Covetrus.

What is Covetrus' official website?

The official website for Covetrus is http://www.henryscheinvet.com/.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at 888-280-2221 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel